$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Correct usage and recommended dosage of molotinib
2026-02-01 22:25:32
Check Details
Common adverse reactions and prevention of molotinib (Ojjaara)
2026-02-01 22:25:32
Check Details
Molotinib drug introduction and marketing information
2026-02-01 22:25:32
Check Details
Indications of Capmatinib (Capatinib)
2026-02-01 22:25:32
Check Details
How long does it take to stop taking Capmatinib?
2026-02-01 22:25:32
Check Details
Contraindications for the lung cancer targeted drug capmatinib (capatinib)
2026-02-01 22:25:32
Check Details
Which generation of targeted drugs does Selinisol (Silvio) belong to?
2026-02-01 22:25:32
Check Details
How effective is Selinisol (Silvio) in treating leukemia?
2026-02-01 22:25:32
Check Details
Efficacy of selinesol (silvio) in the treatment of multiple myeloma
2026-02-01 22:25:32
Check Details
Selinexol (Silvio) side effects and side effects management
2026-02-01 22:25:32
Check Details
Analysis of the medical insurance reimbursement policy for enzalutamide/enzalutamide in 2024
2026-02-01 22:25:32
Check Details
Is enzalutamide/enzalutamide effective for all men with prostate cancer?
2026-02-01 22:25:32
Check Details
1
2
...
816
817
818
819
820
821
822
...
10223
10224
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
2
Avatrombopag Complete Guide: Efficacy, Indications, and TPO-RA Drug Comparisons
3
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
4
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
5
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
6
Elagolix Side Effects and Safety Guide
7
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
8
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
9
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
10
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
11
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
12
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management